omodenbamab
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2015 (NCT02357966)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Staphylococcus aureus subsp. aureusImmunity, passive
Staphylococcus aureus subsp. aureus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594339 ↗
Also known as
- 514g3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02357966 | Phase 1/Phase 2 (Phase 2) | May 1, 2015 | University of Nebraska, XBiotech, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Nebraska | Academic/Hospital | 1 | 0 | 1 | 2015 |
| XBiotech, Inc. | For profit | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1